A Study of VET3-TGI in Patients With Solid Tumors

Key Who May Qualify: - Have pathologically confirmed, advanced, unresectable, or metastatic solid tumors. Preferred indications include, but are not limited to, breast carcinoma, bladder carcinoma, cervical squamous carcinoma, colorectal carcinoma, esophageal carcinoma, head and neck squamous carcinoma, renal cell carcinoma, ovarian carcinoma, sarcoma, thymoma, and uterine carcinoma. - Failed, intolerant to, or refused potentially curative treatment options, including but not limited to, standard of care molecularly targeted agents, immunotherapy (e.g., anti -pembrolizumab/PDL1 antibodies), and chemotherapy - Measurable disease as per RECIST 1.1 criteria - At least one tumor amenable to safe ITu injections and/or biopsies - You should be able to carry out daily activities with 0 level of ability (ECOG 0) or 1 - Demonstrate your organs (liver, kidneys, etc.) are working well enough based on blood tests - Must be willing to comply with all protocol procedures and adhere to post-treatment care instructions Additional Inclusion criteria exist Key Who Should NOT Join This Trial: - previous cancer treatment that works throughout the body (like chemotherapy) washout (dependent upon the therapy) - Requires use of anti-platelet or anti-coagulant therapy that cannot be safely suspended for per protocol biopsies or intra-tumoral injections. - cancer that has spread to the brain and/or carcinomatous meningitis that have not been completely resected or completely irradiated. - Prior history of myocarditis - Known HIV/AIDS, active HBV or HCV infection. - Receiving high dose immunosuppressive medication or has a significant weakened immune system (e.g. transplant recipient, etc). Additional Exclusion criteria exist Always talk to your doctor about whether this trial is right for you.